News and Events

News

All categories

Earnings

Press Release

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Present at the Cantor Global Healthcare Conference 2024

September 10, 2024

Affimed Reports Second Quarter 2024 Financial Results & Business Update

September 5, 2024

Affimed Appoints Shawn M. Leland as Chief Executive Officer

September 3, 2024

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

August 29, 2024

Affimed Reports First Quarter 2024 Financial Results & Business Update

June 12, 2024

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

June 5, 2024

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

June 1, 2024

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

May 29, 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

May 23, 2024

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

May 14, 2024

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Present at the Cantor Global Healthcare Conference 2024

Affimed Reports Second Quarter 2024 Financial Results & Business Update

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Events